A case report published in Frontiers in Neuroscience describes a woman with advanced Alzheimer’s disease who experienced significant improvements in brain function after taking psilocybin-containing mushrooms. The study focused on a Japanese American woman who had lived with Alzheimer’s for approximately 10 years, experiencing severe functional decline for roughly five years.
The patient presented with advanced dementia, very limited speech or communication, severe cognitive impairment, urinary incontinence, and reduced mobility, requiring caregiver assistance for daily living activities. She received two doses of psilocybin: a 5-gram oral dose, followed by a 3-gram dose one month later. After the first dose, she experienced profuse sweating and hyperthermia followed by a prolonged sleep-like state. Approximately 19 hours later, she “spontaneously initiated autobiographical conversation lasting several hours,” according to the researchers. Over the following days and weeks, she experienced restored urinary continence, walked independently, dressed herself, engaged in spontaneous conversation, retrieved contextual memories, expressed emotions, and maintained eye contact and smiling.
After the second session, improvements became more pronounced: the woman had greater speech capabilities, more facial expressions and humor, increased walking agility, and continued continence. Beyond the heavy sweating, hyperthermia, and initial sleep-like state, she did not experience severe or persistent adverse effects. The reported benefits lasted for at least one month, though the paper provides no longer-term follow-up.
However, researchers emphasized substantial limitations: the study involved only a single patient with no control group, standardized cognitive assessments, brain imaging biomarkers, or electrophysiological monitoring. The patient’s Alzheimer’s diagnosis was not confirmed with modern biomarkers, and other neurodegenerative conditions could not be completely ruled out. As such, researchers cannot establish that psilocybin directly caused the improvements, as the patient may have experienced natural fluctuations in her condition. Controlled clinical trials, cognitive assessments, and imaging scans are needed before drawing conclusions about psilocybin’s safety and effectiveness for dementia.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://newspub.live/health/woman-with-advanced-alzheimers-regained-speech-and-memories-after-taking-magic-mushrooms/